These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2401870)

  • 1. HMG-CoA reductase inhibitors.
    Grundy SM
    J Intern Med; 1990 Sep; 228(3):201-5. PubMed ID: 2401870
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
    Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
    Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
    [No Abstract]   [Full Text] [Related]  

  • 3. Phytoconstituents of an ethanolic pod extract of Prosopis cineraria triggers the inhibition of HMG-CoA reductase and the regression of atherosclerotic plaque in hypercholesterolemic rabbits.
    Ram H; Jaipal N; Charan J; Kashyap P; Kumar S; Tripathi R; Singh BP; Siddaiah CN; Hashem A; Tabassum B; Abd Allah EF
    Lipids Health Dis; 2020 Jan; 19(1):6. PubMed ID: 31931807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Density Lipoprotein Measurement Discordance: When 2 Wrongs Lead to the Right Answer-Elevated Lipoprotein (a).
    Intwala S; Stone NJ; Balady GJ
    JAMA Cardiol; 2017 Jun; 2(6):697-698. PubMed ID: 28355452
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HMG-CoA reductase inhibitors].
    Yamamoto A
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
    Farnier M
    Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
    Bocan TM; Mueller SB; Brown EQ; Lee P; Bocan MJ; Rea T; Pape ME
    Atherosclerosis; 1998 Jul; 139(1):21-30. PubMed ID: 9699888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New possibilities of correction of hypercholesterolemia in patients with diabetes mellitus].
    Pan'kiv VI
    Lik Sprava; 2014; (5-6):56-67. PubMed ID: 25906648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol--frequently asked questions.
    Phillips PJ; Phillipov G
    Aust Fam Physician; 2006 Aug; 35(8):595-6. PubMed ID: 16894432
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy and clinical trials: HDL-cholesterol and niacin therapy--past, present, and future.
    Virani SS; Ballantyne CM
    Curr Opin Lipidol; 2010 Apr; 21(2):165-6. PubMed ID: 20616632
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy and tolerability of statins in patients with primary hyperlipidemias].
    Rozhkova TA; Susekov AV; Solov'eva EIu; Titov VN; Kukharchuk VV
    Kardiologiia; 2005; 45(9):32-4. PubMed ID: 16234790
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention and treatment of coronary heart disease: lowering LDL, increasing HDL or monitoring both?].
    Windler E
    Internist (Berl); 1996 Jun; 37(6):643-6. PubMed ID: 8768000
    [No Abstract]   [Full Text] [Related]  

  • 14. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
    Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
    Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment.
    Fentoğlu O; Sözen T; Oz SG; Kale B; Sönmez Y; Tonguç MO; Gürgan CA; Aykaç Y; Kirzioğlu FY
    Oral Dis; 2010 Oct; 16(7):648-54. PubMed ID: 20412449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of setting standards and guidelines for management of patients with hyperlipidemia].
    Kotake H; Oikawa S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():492-9. PubMed ID: 11347119
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
    Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
    Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Navigating patient preference and guidelines as a fellow.
    Gosain P
    J Am Coll Cardiol; 2015 Feb; 65(4):398-400. PubMed ID: 25634841
    [No Abstract]   [Full Text] [Related]  

  • 19. Response: “Actually, it’s more of a guideline than a rule”.
    Halperin JL
    J Am Coll Cardiol; 2015 Feb; 65(4):400. PubMed ID: 25793247
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-related statin myopathy: is it an issue?
    Wortmann RL
    Cleve Clin J Med; 2005 Sep; 72(9):751-3, 756. PubMed ID: 16193823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.